In a small series of human trials of CD19-CAR T cell therapy for systemic lupus erythematosus (SLE), patients who received autologous CAR T cell therapy experienced significant in vivo CAR T cell expansion, swift alleviation of lupus symptoms, but little to no adverse events (87, 88). The gene discussed is CD19; the disease is systemic lupus erythematosus.